Our portfolio companies are currently developing diagnostics for early detection of cancer via blood sample, saving lives in emergency care and surgery through software innovations, developing personalised treatments of severe diseases, and much more.
PeptiSystems has developed a groundbreaking technology for the large-scale production of precision drugs. The company sells instruments for manufacturing peptides and oligonucleotides used in pharmaceutical manufacturing.
Akiram has developed a new type of targeted radioimmunotherapy with the potential to become first-in-class. In animal studies, the survival rate has been 100%, and the tumours have been eradicated with just one treatment.
Encare not only contributes to more cost-effective surgery but also reduces complications and saves lives through their proprietary software solution that helps hospitals implement best practice throughout the entire care chain – from diagnosis and preparation to surgery and rehabilitation.
The company has developed a DNA sequencing solution with significantly improved performance compared with current alternatives. The market is growing rapidly in terms of both research and clinical applications.
Former portfolio companies that have reached new heights through acquisition or listing, and continue to thrive under new ownership. These companies continue to make a lasting impact in their respective industries.
Inhalation Science’s technology is used by leading players in the chemical and pharmaceutical sectors to study how airborne particles affect the human body.
